University of California Berkeley seal E. O. Lawrence Berkeley National Laboratory seal
The Carcinogenic Potency Project

1,3-Butadiene (CAS 106-99-0)
SMILES, InChI and Structure are below.
Rats and Mice: Cancer Test Summary
Rat Target Sites Mouse Target Sites TD50 (mg/kg/day)
Male Female Male Female Rat Mouse
tes mgl hag hmo kid liv lun nrv pre sto vsc hag hmo liv lun mgl ova sto vsc 261m,v 13.9m,v

Key to the Table Above

Positivity: For each chemical with a positive (carcinogenic) experiment in the Carcinogenic Potency Database (CPDB), results are included on carcinogenic potency (TD50) in each species and target sites in males and females. Positivity is determined by an author’s opinion in a published paper. If all experimental results in the CDPB are negative in a sex-species group, “no positive” appears. If the CPDB has no experiments in the sex-species group, “no test” appears. The summary presents the strongest evidence of carcinogenicity in each group. If there are both positive and negative experiments in a sex-species, the negative results are ignored in this Summary Table.
Target Site Codes:   hag = harderian gland. hmo = hematopoietic system. kid = kidney. liv = liver. lun = lung. mgl = mammary gland. nrv = nervous system. ova = ovary. pre = preputial gland. sto = stomach. tes = testes. vsc = vascular system. Target sites are listed if any author of published experimental results concluded that tumors were induced in that organ by the test agent. If there is more than one positive experiment in a sex-species, target sites listed may be from more than one experiment, e.g. if liver and lung are both listed, then liver may have been a target in one experiment and lung in another.
TD50: Our standardized measure of carcinogenic potency, TD50, is the daily dose rate in mg/kg body weight/day to induce tumors in half of test animals that would have remained tumor-free at zero dose. Whenever there is more than one positive experiment in a species, the reported TD50 value is a Harmonic Mean calculated using the TD50 value from the most potent target site in each positive experiment.
Superscripts:   m = There is more than one positive experiment in the species, and TD50 values from each positive experiment are used in the calculation of the reported Harmonic mean of TD50. v = Variation is greater than ten-fold among statistically significant (two-tailed p<0.1) TD50 values from different positive experiments.

The Carcinogenic Potency Database (CPDB) is a unique and widely used international resource of the results of 6540 chronic, long-term animal cancer tests on 1547 chemicals. The CPDB provides easy access to the bioassay literature, with qualitative and quantitative analyses of both positive and negative experiments that have been published over the past 50 years in the general literature through 2001 and by the National Cancer Institute/National Toxicology Program through 2004. The CPDB standardizes the diverse literature of cancer bioassays that vary widely in protocol, histopathological examination and nomenclature, and in the published author’s choices of what information to provide in their papers. Results are reported in the CPDB for tests in rats, mice, hamsters, dogs, and nonhuman primates.

For each experiment, information is included on species, strain, and sex of test animal; features of experimental protocol such as route of administration, duration of dosing, dose level(s) in mg/kg body weight/day, and duration of experiment; experimental results are provided on target organ, tumor type, and tumor incidence; carcinogenic potency (TD50) and its statistical significance; shape of the dose-response, author’s opinion as to carcinogenicity, and literature citation.

Only tests with dosing for at least ¼ the standard lifespan of the species and experiment length at least ½ the lifespan are included in the CPDB. Only routes of administration with whole body exposure are included. Doses are standardized, average dose rates in mg/kg/day. A description of methods used in the CPDB to standardize the diverse literature of animal cancer tests is presented for: 1) Criteria for inclusion of experiments 2) Standardization of average daily dose levels and 3) TD50 estimation for a standard lifespan. See Methods for other details.

TD50 provides a standardized quantitative measure that can be used for comparisons and analyses of many issues in carcinogenesis. The range of TD50 values across chemicals that are rodent carcinogens is more than 100 million-fold. More than half the chemicals tested are positive in at least one experiment.

A plot of all results on each experiment in the CPDB for this chemical is presented below. These results are the source information for the Cancer Test Summary table above.

1,3-Butadiene: All Experiments and Citations in CPDB

The definition of each code in the plot below will appear in a pop-up window when the field name in the header line is clicked, e.g., Strain, Site, Path. Each numbered line starts a new experiment and reports protocol information in black. Average daily dose-rates per kg body weight per day are in green. Remaining lines report experimental results in blue.

Abbreviations of fields in header line: # = the line number in the plot of all CPDB chemicals; Xpo = duration of dosing; Xpt = duration of experiment; Site = tissue; Path = tumor type; DR = dose-response; AuOp = author’s opinion about carcinogenicity; LoConf, UpConf = confidence limits (99%) on TD50; Inc = tumor incidence for each dose group.

See Guide to reading the plot for details on each field, using an example of one experiment.

See Help to improve readability, or to fit the plot onto the screen or a printed page.



Chemical (Synonym) CAS
# Species Sex Strain Route Xpo+Xpt PaperNum        0 Dose  1 Dose 2 Dose  3 Dose          Literature Reference or NCI/NTP:Site Path
Site Path Notes   TD50  DR Pval    AuOp LoConf UpConf   Cntrl   1 Inc  2 Inc   3 Inc                                                        Brkly Code

1,3-BUTADIENE 106-99-0 867 M f b6c inh 61w61 TR288 : 0 435.mg 869.mg MXB MXB 53.0mg \ P<.0005 30.6mg 106.mg 4/50 30/50 (44/50) ---:mno; for:sqp; hea:hes; liv:hpa,hpc; lun:a/a,a/c; mgl:acc; ova:gcc,gct. C MXA hes 147.mg \ P<.0005 73.4mg 333.mg 0/50 13/50 (19/50) hea:hes; liv:hes; sub:hes. S lun MXA 203.mg * P<.0005 c 126.mg 411.mg 3/50 12/50 23/50 lun:a/a,a/c. lun a/c 227.mg \ P<.0005 c 91.8mg 825.mg 0/50 6/50 (8/50) lun a/a 259.mg * P<.0005 c 153.mg 585.mg 3/50 9/50 20/50 --- mno 270.mg \ P<.0005 c 114.mg 1.03gm 1/50 10/50 (10/50) hea hes 283.mg * P<.0005 c 179.mg 483.mg 0/50 11/50 18/50 ova MXA 370.mg * P<.0005 c 214.mg 728.mg 0/50 6/50 13/50 ova:gcc,gct. for MXA 396.mg \ P<.002 133.mg 2.44gm 0/50 4/50 (1/50) for:sqc,sqp. S for sqp 461.mg \ P<.005 c 140.mg 5.15gm 0/50 3/50 (1/50) for MXA 462.mg * P<.0005 252.mg 1.03gm 0/50 5/50 10/50 for:ppn,sqc,sqp. S for MXA 483.mg * P<.0005 259.mg 1.10gm 0/50 4/50 10/50 for:ppn,sqp. S mgl acc 1.03gm * P<.002 c 462.mg 4.19gm 0/50 2/50 6/50 liv MXA 1.17gm * P<.004 c 496.mg 6.82gm 0/50 2/50 5/50 liv:hpa,hpc. liv hpa 1.59gm * P<.009 c 596.mg 36.9gm 0/50 1/50 4/50 ova gcc 7.58gm * P<.2 c 1.23gm n.s.s. 0/50 0/50 1/50 TBA MXB 41.5mg \ P<.0005 25.1mg 75.8mg 6/50 40/50 (46/50) liv MXB 1.17gm * P<.004 496.mg 6.82gm 0/50 2/50 5/50 liv:hpa,hpc,nnd. lun MXB 203.mg * P<.0005 126.mg 411.mg 3/50 12/50 23/50 lun:a/a,a/c. 868 M f b6c inh 19m24 TR434 : 0 4.26mg 13.7mg 42.8mg 139.mg 435.mg MXB MXB a 6.79mg Z P<.0005 4.92mg 9.63mg 28/50 36/50 39/50 45/50 48/50 71/80 ---:hcs,mlm,mlp,mlu,mly; for: sqc,sqp; hag:adc,ade,anb; hea:hes; liv:hpa,hpc; lun:a/a,a/c,adc; mgl:adc,ado,mtm; ova:ade,gcb,gcm, mtb. C lun MXA a 12.4mg Z P<.0005 c 8.55mg 19.5mg 4/50 15/50 19/50 24/50 25/50 22/80 lun:a/a,a/c,adc. lun a/a a 20.3mg Z P<.0005 12.9mg 35.5mg 4/50 11/50 12/50 17/50 14/50 17/80 S liv MXA a 22.8mg * P<.0005 c 13.7mg 44.6mg 15/50 14/50 15/50 19/50 16/50 2/80 liv:hpa,hpc. lun MXA a 23.9mg Z P<.0005 15.3mg 39.1mg 0/50 5/50 11/50 9/50 19/50 8/80 lun:a/c,adc. S hag MXA a 26.2mg Z P<.0005 c 16.1mg 47.2mg 8/50 10/50 7/50 15/50 20/50 9/80 hag:adc,ade,anb. hag MXA a 26.2mg Z P<.0005 16.1mg 47.3mg 8/50 10/50 6/50 15/50 20/50 9/80 hag:ade,anb. S --- MXA a 27.4mg Z P<.0005 16.3mg 50.9mg 9/50 14/50 18/50 11/50 16/50 36/80 ---:hcs,mlm,mlp,mlu,mly. S liv hpa a 28.5mg Z P<.0005 16.3mg 61.6mg 11/50 10/50 9/50 14/50 12/50 (1/80) S --- MXA a 35.0mg Z P<.0005 21.6mg 59.1mg 5/50 3/50 3/50 9/50 24/50 27/80 ---:hem,hes. S --- MXA a 35.2mg Z P<.0005 c 19.6mg 74.7mg 6/50 12/50 11/50 7/50 9/50 32/80 ---:mlm,mlp,mlu,mly. --- hes a 44.2mg Z P<.0005 26.3mg 75.0mg 3/50 2/50 2/50 5/50 23/50 27/80 S mgl MXA a 47.4mg * P<.0005 c 28.0mg 80.9mg 0/50 2/50 4/50 12/50 15/50 16/80 mgl:adc,ado,mtm. liv hpc a 50.5mg * P<.0005 26.6mg 125.mg 4/50 6/50 8/50 9/50 8/50 1/80 S ova MXA a 65.4mg * P<.0005 c 34.9mg 133.mg 1/50 0/50 1/50 9/50 8/50 6/80 ova:gcb,gcm. --- mlp a 74.9mg * P<.0005 c 36.6mg 171.mg 1/50 3/50 6/50 3/50 8/50 31/80 ova MXA a 78.9mg * P<.0005 c 35.1mg 256.mg 2/50 4/50 1/50 4/50 6/50 2/80 ova:ade,mtb. for MXA a 83.9mg Z P<.0005 c 39.8mg 192.mg 0/50 0/50 3/50 2/50 4/50 22/80 for:sqc,sqp. mgl ado a 87.7mg * P<.0005 40.5mg 237.mg 0/50 1/50 2/50 6/50 4/50 0/80 S mgl adc a 93.3mg * P<.0005 49.3mg 174.mg 0/50 2/50 2/50 6/50 11/50 12/80 S ova MXA a 98.0mg * P<.0005 47.4mg 235.mg 1/50 0/50 1/50 6/50 6/50 6/80 ova:gcb,glb. S hea hes a 104.mg Z P<.0005 c 60.0mg 161.mg 0/50 0/50 0/50 1/50 21/50 23/80 --- hcs a 125.mg * P<.0005 c 54.2mg 431.mg 3/50 2/50 7/50 4/50 7/50 4/80 for sqp a 126.mg Z P<.0005 51.7mg 337.mg 0/50 0/50 2/50 1/50 3/50 16/80 S sub MXA a 128.mg * P<.0005 e 57.9mg 434.mg 1/50 2/50 3/50 5/50 3/50 3/80 sub:nfs,sar. sub sar a 131.mg * P<.0005 58.8mg 437.mg 1/50 2/50 2/50 5/50 3/50 3/80 S ova gcm a 198.mg * P<.0005 68.7mg 790.mg 0/50 0/50 0/50 3/50 2/50 0/80 S ova mtb a 202.mg * P<.0005 73.1mg 622.mg 0/50 0/50 0/50 2/50 5/50 1/80 S for sqc a 257.mg * P<.0005 77.9mg 1.04gm 0/50 0/50 1/50 1/50 1/50 6/80 S kid rua a 1.06gm * P<.01 e 199.mg 246.gm 0/50 0/50 0/50 0/50 2/50 0/80 mgl mtm a 2.71gm * P<.0005 869.mg 13.2gm 0/50 0/50 0/50 0/50 0/50 4/80 S zym MXA a 3.54gm * P<.004 e 808.mg 55.7gm 0/50 0/50 0/50 0/50 0/50 2/80 zym:ade,car. ova ade a 217.mg * P<.03 55.2mg n.s.s. 2/50 4/50 1/50 2/50 1/50 1/80 S TBA MXB a 6.28mg Z P<.0005 4.65mg 8.91mg 35/50 47/50 43/50 48/50 49/50 72/80 liv MXB a 22.8mg * P<.0005 13.7mg 44.6mg 15/50 14/50 15/50 19/50 16/50 2/80 liv:hpa,hpc,nnd. lun MXB a 13.8mg Z P<.0005 9.48mg 21.9mg 4/50 13/50 18/50 22/50 24/50 22/80 lun:a/a,a/c. 869 M m b6c inh 60w60 TR288 : 0 362.mg 724.mg MXB MXB 28.8mg \ P<.0005 17.5mg 50.0mg 2/50 43/50 (39/50) ---:mno; for:ppn,sqp; hea:hes; lun:a/a,a/c. C lun MXA 65.9mg * P<.0005 c 38.7mg 128.mg 2/50 14/50 15/50 lun:a/a,a/c. hea hes 96.7mg \ P<.0005 c 51.1mg 198.mg 0/50 16/50 (7/50) MXA hes 96.7mg \ P<.0005 51.1mg 198.mg 0/50 16/50 (8/50) hea:hes; pec:hes. S lun a/a 96.9mg * P<.0005 c 54.4mg 203.mg 2/50 12/50 11/50 --- mno 105.mg * P<.0005 c 70.1mg 158.mg 0/50 23/50 29/50 for MXA 120.mg \ P<.0005 49.6mg 391.mg 0/50 7/50 (1/50) for:ppn,sqc,sqp. S for MXA 140.mg \ P<.0005 c 53.3mg 600.mg 0/50 5/50 (0/50) for:ppn,sqp. lun a/c 312.mg * P<.0005 c 126.mg 1.08gm 0/50 2/50 5/50 pre MXA 403.mg * P<.002 150.mg 1.92gm 0/50 3/50 2/50 pre:can,sqc. S pre sqc 538.mg * P<.004 181.mg 4.83gm 0/50 3/50 1/50 S for MXA 557.mg * P<.004 197.mg 4.31gm 0/50 4/50 1/50 for:sqc,sqp. S TBA MXB 28.8mg \ P<.0005 17.3mg 52.5mg 10/50 44/50 (40/50) liv MXB 541.mg * P<.2 149.mg n.s.s. 8/50 6/50 2/50 liv:hpa,hpc,nnd. lun MXB 65.9mg * P<.0005 38.7mg 128.mg 2/50 14/50 15/50 lun:a/a,a/c. 870 M m b6c inh 19m24 TR434 : 0 3.55mg 11.4mg 35.6mg 114.mg 362.mg MXB MXB a 10.7mg Z P<.0005 7.80mg 15.3mg 42/50 38/50 44/50 47/50 49/50 62/73 ---:hcs,mlh,mlm,mlp,mlu,mly; for:sqc,sqp; hag:adc,ade,anb; hea:hes; kid:rua; liv:hpa,hpc; lun:a/a,a/c,adc; pre:car. C lun MXA a 19.2mg * P<.0005 c 12.6mg 32.9mg 21/50 23/50 19/50 31/50 35/50 3/73 lun:a/a,a/c,adc. liv MXA a 23.9mg Z P<.0005 c 14.9mg 43.3mg 21/50 23/50 30/50 25/50 33/50 5/73 liv:hpa,hpc. hag MXA a 26.1mg Z P<.0005 c 17.5mg 41.5mg 6/50 7/50 9/50 20/50 31/50 6/73 hag:adc,ade,anb. hag MXA a 27.6mg Z P<.0005 18.4mg 45.0mg 6/50 7/50 8/50 19/50 30/50 6/73 hag:ade,anb. S lun MXA a 32.4mg Z P<.0005 20.5mg 58.0mg 5/50 6/50 11/50 12/50 22/50 3/73 lun:a/c,adc. S lun a/a a 33.2mg * P<.0005 19.7mg 69.3mg 18/50 20/50 10/50 25/50 21/50 3/73 S liv hpa a 34.1mg Z P<.0005 20.5mg 65.6mg 13/50 13/50 19/50 16/50 24/50 5/73 S liv hpc a 34.4mg * P<.0005 20.5mg 68.2mg 11/50 16/50 16/50 17/50 26/50 1/73 S --- MXA a 38.0mg Z P<.0005 24.5mg 63.4mg 2/50 5/50 3/50 11/50 24/50 4/73 ---:hem,hes. S --- hes a 45.5mg Z P<.0005 28.6mg 78.7mg 1/50 4/50 3/50 7/50 24/50 4/73 S --- MXA a 63.5mg Z P<.0005 40.8mg 101.mg 4/50 2/50 8/50 11/50 9/50 55/73 ---:hcs,mlh,mlm,mlp,mlu,mly. S hea hes a 64.8mg Z P<.0005 c 38.8mg 114.mg 0/50 0/50 1/50 5/50 20/50 4/73 --- MXA a 99.8mg Z P<.0005 c 60.0mg 174.mg 4/50 2/50 4/50 6/50 2/50 51/73 ---:mlh,mlm,mlp,mlu,mly. --- hcs a 157.mg * P<.0005 c 82.9mg 372.mg 0/50 0/50 4/50 5/50 7/50 4/73 --- mlp a 157.mg Z P<.0005 c 93.7mg 248.mg 2/50 0/50 2/50 4/50 2/50 49/73 for MXA a 197.mg Z P<.0005 c 91.0mg 494.mg 1/50 0/50 0/50 1/50 8/50 4/73 for:sqc,sqp. hag adc a 221.mg * P<.005 85.7mg 3.26gm 0/50 1/50 1/50 3/50 2/50 0/73 S for sqp a 230.mg Z P<.0005 98.7mg 674.mg 1/50 0/50 0/50 1/50 7/50 2/73 S pre car a 384.mg * P<.0005 c 131.mg 1.52gm 0/50 0/50 0/50 0/50 5/50 0/73 kid rua a 268.mg * P<.02 c 92.1mg n.s.s. 0/50 1/50 0/50 3/50 1/50 0/73 jej car a 310.mg * P<.02 e 97.0mg n.s.s. 0/50 1/50 1/50 1/50 2/50 0/73 sub hes a 666.mg * P<.03 164.mg n.s.s. 0/50 1/50 1/50 0/50 3/50 0/73 S bra onm a no dre P=1. n.s.s. n.s.s. 0/50 0/50 0/50 0/50 0/50 0/73 bra ogm a no dre P=1. n.s.s. n.s.s. 0/50 0/50 0/50 0/50 0/50 0/73 TBA MXB a 10.5mg Z P<.0005 7.76mg 15.1mg 44/50 40/50 45/50 48/50 49/50 62/73 liv MXB a 23.9mg Z P<.0005 14.9mg 43.3mg 21/50 23/50 30/50 25/50 33/50 5/73 liv:hpa,hpc,nnd. lun MXB a 19.6mg * P<.0005 12.8mg 33.8mg 21/50 23/50 18/50 30/50 35/50 3/73 lun:a/a,a/c. 871 M m b6c inh 12m24 TR434a : 0 90.3mg MXB MXB 6.12mg P<.0005 3.14mg 12.8mg 38/50 50/50 ---:hcs,mlm,mlp,mly; for:sqc,sqp; hag:adc,ade,adi,anb; hea:hes; kid:ade,rua; liv:hpa; lun:a/a,a/c,adc; pre:car,cnb. C lun MXA 7.17mg P<.0005 c 3.25mg 17.2mg 21/50 32/50 lun:a/a,a/c,adc. lun a/a 9.13mg P<.0005 3.90mg 24.2mg 18/50 26/50 S --- MXA 11.1mg P<.0005 3.83mg 29.2mg 2/50 34/50 ---:hem,hes. S --- hes 11.9mg P<.0005 3.99mg 30.6mg 1/50 34/50 S lun MXA 13.0mg P<.0005 4.19mg 45.1mg 5/50 16/50 lun:a/c,adc. S hag MXA 13.1mg P<.0005 c 5.55mg 30.1mg 6/50 30/50 hag:adc,ade,adi,anb. liv MXA 13.8mg P<.0005 5.73mg 38.4mg 21/50 25/50 liv:hpa,hpb,hpc. S hea hes 13.9mg P<.0005 c 4.42mg 30.6mg 0/50 33/50 liv MXA 14.6mg P<.0005 5.90mg 42.0mg 21/50 24/50 liv:hpa,hpc. S hag MXA 14.9mg P<.0005 5.97mg 35.0mg 6/50 28/50 hag:ade,anb. S liv hpa 15.8mg P<.0005 c 5.76mg 51.1mg 13/50 19/50 pre MXA 20.1mg P<.0005 c 4.83mg 145.mg 0/50 4/50 pre:car,cnb. --- MXA 27.6mg P<.0005 7.97mg 102.mg 4/50 15/50 ---:hcs,mlm,mlp,mly. S liv MXA 41.4mg P<.0005 13.5mg 226.mg 11/50 11/50 liv:hpb,hpc. S for MXA 42.8mg P<.0005 c 7.30mg 203.mg 1/50 9/50 for:sqc,sqp. --- MXA 46.4mg P<.0005 c 9.93mg 342.mg 4/50 8/50 ---:mlm,mlp,mly. liv hpc 47.0mg P<.002 14.4mg 341.mg 11/50 10/50 S --- MXA 76.2mg P<.006 14.4mg 2.13gm 2/50 4/50 ---:mlm,mly. S for sqp 77.7mg P<.004 8.51mg 1.67gm 1/50 4/50 S hag MXA 88.9mg P<.007 15.0mg 1.69gm 0/50 2/50 hag:adc,adi. S --- hcs 110.mg P<.0005 c 32.2mg 434.mg 0/50 7/50 for sqc 154.mg P<.0005 54.0mg 670.mg 0/50 5/50 S kid MXA 190.mg P<.003 c 44.1mg 2.09gm 0/50 3/50 kid:ade,rua. --- mlp 129.mg P<.03 c 12.9mg n.s.s. 2/50 4/50 bra onm no dre P=1. n.s.s. n.s.s. 0/50 0/50 bra ogm no dre P=1. n.s.s. n.s.s. 0/50 0/50 --- hem no dre P=1. 18.8mg n.s.s. 1/50 0/50 zym ade no dre P=1. 18.8mg n.s.s. 1/50 0/50 zym car no dre P=1. n.s.s. n.s.s. 0/50 0/50 TBA MXB 5.84mg P<.0005 3.03mg 12.3mg 44/50 50/50 liv MXB 14.6mg P<.0005 5.90mg 42.0mg 21/50 24/50 liv:hpa,hpc,nnd. lun MXB 7.25mg P<.0005 3.27mg 17.6mg 21/50 31/50 lun:a/a,a/c. 872 M m b6c inh 9m24 TR434b : 0 44.5mg MXB MXB 10.9mg P<.0005 5.96mg 27.1mg 38/50 47/50 ---:hcs,mlm,mlp,mly; for:sqc,sqp; hag:adc,ade,anb; hea:hes; kid: rua; liv:hpa; lun:a/a,a/c; pre:car,cnb. C lun MXA 11.0mg P<.0005 c 5.99mg 25.4mg 21/50 36/50 lun:a/a,a/c. lun a/c 16.3mg P<.0005 8.37mg 38.5mg 5/50 22/50 S liv MXA 16.8mg P<.0005 8.75mg 44.4mg 21/50 33/50 liv:hpa,hpc. S --- MXA 17.3mg P<.0005 9.19mg 38.5mg 2/50 20/50 ---:hem,hes. S hag MXA 17.5mg P<.0005 c 9.53mg 37.5mg 6/50 27/50 hag:adc,ade,anb. hag MXA 18.0mg P<.0005 9.67mg 39.1mg 6/50 26/50 hag:ade,anb. S liv hpa 18.0mg P<.0005 c 9.14mg 46.7mg 13/50 27/50 lun a/a 18.1mg P<.0005 8.53mg 63.0mg 18/50 24/50 S --- hes 20.8mg P<.0005 10.8mg 47.6mg 1/50 17/50 S hea hes 21.9mg P<.0005 c 11.1mg 48.2mg 0/50 15/50 --- MXA 57.1mg P<.002 24.5mg 259.mg 4/50 13/50 ---:hcs,mlm,mlp,mly. S --- hcs 128.mg P<.002 c 44.7mg 670.mg 0/50 5/50 kid rua 161.mg P<.005 c 49.3mg 1.60gm 0/50 4/50 liv hpc 62.0mg P<.02 23.9mg n.s.s. 11/50 14/50 S --- hem 95.2mg P<.02 27.8mg n.s.s. 1/50 4/50 S --- MXA 108.mg P<.03 c 34.5mg n.s.s. 4/50 8/50 ---:mlm,mlp,mly. --- mlp 142.mg P<.04 c 41.0mg n.s.s. 2/50 6/50 for sqp 171.mg P<.06 41.5mg n.s.s. 1/50 3/50 for MXA 171.mg P<.06 c 41.5mg n.s.s. 1/50 3/50 for:sqc,sqp. pre MXA 351.mg P<.1 57.1mg n.s.s. 0/50 1/50 pre:ade,car,cnb. pre MXA 351.mg P<.1 c 57.1mg n.s.s. 0/50 1/50 pre:car,cnb. hag adc 531.mg P<.07 130.mg n.s.s. 0/50 2/50 --- MXA 487.mg P<.5 63.3mg n.s.s. 2/50 2/50 ---:mlm,mly. zym car 625.mg P<.2 102.mg n.s.s. 0/50 1/50 zym MXA 647.mg P<.5 62.7mg n.s.s. 1/50 1/50 zym:ade,car. bra onm no dre P=1. n.s.s. n.s.s. 0/50 0/50 bra ogm no dre P=1. n.s.s. n.s.s. 0/50 0/50 TBA MXB 10.8mg P<.0005 5.83mg 28.7mg 44/50 49/50 liv MXB 16.8mg P<.0005 8.75mg 44.4mg 21/50 33/50 liv:hpa,hpc,nnd. lun MXB 11.0mg P<.0005 5.99mg 25.4mg 21/50 36/50 lun:a/a,a/c. 873 M m b6c inh 6m24 TR434c : 0 90.5mg MXB MXB 12.6mg P<.0005 6.27mg 24.4mg 38/50 49/50 ---:hcs,mlm,mlp,mly; bra:ogm; for:sqc,sqp; hag:adc,ade,adi,anb; hea:hes; kid:rua; liv:hpa; lun:a/a,a/c; pre:car,cnb. C lun MXA 13.4mg P<.0005 c 5.01mg 36.8mg 21/50 17/50 lun:a/a,a/c. lun a/a 17.3mg P<.0005 5.62mg 57.0mg 18/50 12/50 S --- hes 17.7mg P<.0005 4.72mg 56.1mg 1/50 14/50 S --- MXA 17.7mg P<.0005 4.72mg 56.1mg 2/50 14/50 ---:hem,hes. S lun a/c 17.8mg P<.0005 4.74mg 62.0mg 5/50 11/50 S hea hes 18.5mg P<.0005 c 4.76mg 64.3mg 0/50 13/50 hag MXA 22.7mg P<.0005 6.72mg 71.9mg 6/50 13/50 hag:ade,anb. S hag MXA 22.7mg P<.0005 c 6.72mg 71.9mg 6/50 13/50 hag:adc,ade,adi,anb. liv MXA 23.8mg P<.0005 8.28mg 77.1mg 21/50 13/50 liv:hpa,hpc. S liv MXA 23.8mg P<.0005 8.28mg 77.1mg 21/50 13/50 liv:hpa,hpb,hpc. S pre MXA 27.1mg P<.0005 c 4.99mg 390.mg 0/50 3/50 pre:car,cnb. pre MXA 27.1mg P<.0005 4.99mg 390.mg 0/50 3/50 pre:ade,car,cnb. S liv hpa 27.8mg P<.0005 c 8.53mg 103.mg 13/50 11/50 --- MXA 28.8mg P<.0005 13.0mg 55.5mg 4/50 35/50 ---:hcs,mlm,mlp,mly. S --- MXA 31.3mg P<.0005 c 13.5mg 62.6mg 4/50 33/50 ---:mlm,mlp,mly. --- mlp 46.0mg P<.0005 c 21.1mg 84.8mg 2/50 30/50 liv MXA 60.0mg P<.004 13.0mg 1.02gm 11/50 4/50 liv:hpb,hpc. S liv hpc 60.0mg P<.004 13.0mg 1.02gm 11/50 4/50 S for MXA 91.4mg P<.0005 c 36.1mg 227.mg 1/50 10/50 for:sqc,sqp. --- MXA 111.mg P<.002 24.5mg 1.19gm 2/50 3/50 ---:mlm,mly. S zym car 135.mg P<.005 e 25.1mg 3.58gm 0/50 2/50 zym MXA 135.mg P<.005 25.1mg 3.58gm 1/50 2/50 zym:ade,car. S for sqc 136.mg P<.0005 41.3mg 533.mg 0/50 6/50 S for sqp 284.mg P<.002 97.1mg 1.71gm 1/50 4/50 S --- hcs 396.mg P<.02 c 90.5mg n.s.s. 0/50 2/50 bra ogm 403.mg P<.05 c 65.7mg n.s.s. 0/50 1/50 kid rua 961.mg P<.1 c 157.mg n.s.s. 0/50 1/50 bra onm no dre P=1. n.s.s. n.s.s. 0/50 0/50 --- hem no dre P=1. n.s.s. n.s.s. 1/50 0/50 TBA MXB 12.5mg P<.0005 6.22mg 24.0mg 44/50 49/50 liv MXB 23.8mg P<.0005 8.28mg 77.1mg 21/50 13/50 liv:hpa,hpc,nnd. lun MXB 13.4mg P<.0005 5.01mg 36.8mg 21/50 17/50 lun:a/a,a/c. 874 M m b6c inh 3m24 TR434d : () 0 45.2mg MXB MXB 7.00mg P<.0005 3.95mg 14.6mg 38/50 49/50 ---:hcs,mlm,mlp,mly; bra:ogm,onm; for:sqc,sqp; hag:adc,ade,adi, anb; hea:hes; kid:rua; liv:hpa; lun:a/a,a/c,adc; pre:car,cnb. C lun MXA 8.59mg P<.0005 c 4.42mg 20.5mg 21/50 28/50 lun:a/a,a/c,adc. hag MXA 11.7mg P<.0005 c 5.73mg 27.0mg 6/50 23/50 hag:adc,ade,adi,anb. lun MXA 14.1mg P<.0005 6.87mg 35.0mg 5/50 18/50 lun:a/c,adc. S hag MXA 14.9mg P<.0005 7.17mg 36.3mg 6/50 20/50 hag:ade,anb. S liv MXA 15.1mg P<.0005 7.17mg 45.5mg 21/50 24/50 liv:hpa,hpc. S liv MXA 15.1mg P<.0005 7.17mg 45.5mg 21/50 24/50 liv:hpa,hpb,hpc. S --- MXA 16.9mg P<.0005 7.78mg 44.7mg 2/50 14/50 ---:hem,hes. S lun a/a 17.1mg P<.0005 7.56mg 68.5mg 18/50 17/50 S liv hpa 17.9mg P<.0005 c 7.86mg 58.2mg 13/50 19/50 --- hes 21.9mg P<.0005 9.92mg 58.7mg 1/50 12/50 S liv MXA 23.4mg P<.0005 9.57mg 99.0mg 11/50 14/50 liv:hpb,hpc. S liv hpc 23.4mg P<.0005 9.57mg 99.0mg 11/50 14/50 S --- MXA 26.2mg P<.0005 12.4mg 61.8mg 4/50 24/50 ---:hcs,mlm,mlp,mly. S hea hes 32.6mg P<.0005 c 12.4mg 108.mg 0/50 7/50 --- MXA 34.9mg P<.0005 c 16.2mg 86.4mg 4/50 22/50 ---:mlm,mlp,mly. for sqc 43.4mg P<.0005 13.4mg 264.mg 0/50 4/50 S for MXA 44.8mg P<.0005 c 14.6mg 226.mg 1/50 7/50 for:sqc,sqp. --- hem 45.8mg P<.003 13.7mg 449.mg 1/50 4/50 S hag MXA 63.5mg P<.0005 19.2mg 358.mg 0/50 4/50 hag:adc,adi. S --- mlp 66.8mg P<.0005 c 33.3mg 175.mg 2/50 17/50 --- hcs 91.1mg P<.007 c 21.1mg 2.84gm 0/50 2/50 pre MXA 119.mg P<.002 43.9mg 550.mg 0/50 5/50 pre:ade,car,cnb. S pre MXA 167.mg P<.004 c 56.7mg 1.32gm 0/50 4/50 pre:car,cnb. --- MXA 78.1mg P<.02 21.6mg n.s.s. 2/50 5/50 ---:mlm,mly. S for sqp 117.mg P<.02 27.3mg n.s.s. 1/50 4/50 S kid rua 201.mg P<.06 c 32.8mg n.s.s. 0/50 1/50 bra ogm 230.mg P<.03 c 51.0mg n.s.s. 0/50 2/50 zym car 336.mg P<.04 e 79.6mg n.s.s. 0/50 2/50 bra onm 394.mg P<.05 c 93.4mg n.s.s. 0/50 2/50 zym MXA 223.mg P<.2 34.2mg n.s.s. 1/50 2/50 zym:ade,car. TBA MXB 6.92mg P<.0005 3.87mg 15.0mg 44/50 49/50 liv MXB 15.1mg P<.0005 7.17mg 45.5mg 21/50 24/50 liv:hpa,hpc,nnd. lun MXB 8.59mg P<.0005 4.42mg 20.5mg 21/50 28/50 lun:a/a,a/c. 875 R f cdr inh 24m24 1829 0 166.mg 1.32gm Owen;amih,48,407-413;1987 mgl mix e 133.mg \ P<.0005 + 78.0mg 341.mg 50/100 79/100 (81/100) mgl ben e 182.mg \ P<.0005 110.mg 428.mg 32/100 64/100 (55/100) thy fca e 8.27gm * P<.0005 4.26gm 24.8gm 0/100 2/100 10/100 mgl mal e 7.72gm * P<.07 2.91gm n.s.s. 18/100 15/100 26/100 tba tum e no dre P=1. 893.mg n.s.s. 97/100 98/100 94/100 876 R m cdr inh 26m26 1829 0 116.mg 927.mg tes ldc e 7.55gm * P<.003 + 3.58gm 52.9gm 0/100 3/100 8/100 pan exa e 9.31gm * P<.006 3.98gm 136.gm 3/100 1/100 10/100 tba tum e 1.47gm * P<.08 550.mg n.s.s. 84/100 70/100 87/100

Mutagenicity in Salmonella: positive
SMILES Code for 1,3-Butadiene: C=CC=C
InChI Code for 1,3-Butadiene: InChI=1/C4H6/c1-3-4-2/h3-4H,1-2H2
Source for SMILES and InChI: USEPA Distributed Structure-Searchable Toxicity (DSSTox) Database
Chemical Structure for 1,3-Butadiene: Chemical Structure
Source for structure: National Library of Medicine ChemIDPlus

See full CPDB Summary Table on 1547 chemicals. See Full CPDB for all results on 6540 experiments of 1547 chemicals.

A complete list of CPDB chemicals, which is searchable by name or by CAS number, is available here.

For a compendium of CPDB results organized by target organ, which lists all chemicals in each species that induced tumors in each of 35 organs, see Summary Table by Target Organ.

The CPDB is available in several formats that permit printing and downloading into spreadsheets and statistical databases.

  1. A plot of the CPDB presents results of 1547 experiments on 6540 chemicals in an easily readable format that has been used in publications of the CPDB.
  2. A Screen version plot for use on a single computer screen, with the same data.
  3. Excel version of the same data.
  4. Tab-separated versions of the same data, which can be easily read into databases.

A Supplementary Dataset gives details on dosing and survival for each experiment.

Relatively precise estimates of the lower confidence limit on the TD10 (LTD10) are readily calculated from the TD50 and its lower confidence limit, which are reported in the CPDB. For researchers and regulatory agencies interested in LTD10 values, we provide them in an Excel spreadsheet.

PDF versions of our publications of analyses using the CPDB are available, organized by year and by research topic.


Carcinogenic Potency Database Project (CPDB) Home Page
For more information about this Web Page, contact Specialized Information Services (tehip@teh.nlm.nih.gov).
Last updated: October 3, 2007


PDF documents are best viewed with the free Adobe® Reader http://get.adobe.com/reader
Excel documents are best viewed with the free Excel® Viewer http://www.microsoft.com/en-us/download/details.aspx?id=10